The relationship between subclassification and prognosis of patients with gastrointestinal diffuse large B-cell lymphoma
- VernacularTitle:胃肠道弥漫性大B细胞淋巴瘤免疫表型与预后的研究
- Author:
Zizhen ZHANG
;
Xingzhi NI
;
Xiaolu YIN
;
Danping SHEN
;
Yanying SHEN
- Publication Type:Journal Article
- Keywords:
Lymphoma,large-cell,diffuse;
Immunophenotyping;
Prognosis;
CD10;
Bcl-6
- From:
Chinese Journal of General Surgery
2008;23(12):946-949
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between tumor subclassifieation and the clinicopathologic features and prognosis of patients with gastrointestinal diffuse large B-cell lymphoma (DLBCL). Method From June 2000 to June 2007, 63 gastrointestinal DLBCL cases were enrolled. Immunohistochemical staining was performed to detect CDIO, Bcl-6 and MUM1 expression. Tumors were subclassified according to CDIO, Bcl-6 and MUM1 expression. Results CD10 expression was positive in 13 cases. Bcl-6 expression was positive in 53 cases. MUM1 expression was positive in 52 cases. According to the expression of CD10, Bcl-6 and MUM1, 17 cases(27%) were of germinal center B cell-like (GCB) DLBCL and 46 cases (73%) were of non-GCB. There was a significant difference in local lymph node metastasis between GCB group and non-GCB group, but there was no significant difference in terms of tumor size and infiltrate depth between the two subgroups. The survival time of patients in GCB group(76 months) was significantly longer than that of non-GCB group (28 months). Among cases receiving postoperative chemotherapy (CHOP), the survival of GCB group (76 months) was longer than non-GCB group (24 months). All 4 GCB cases and 4 non-GCB cases under R-CHOP chemotherapy are alive (22 ～ 47 months). Conclusion Gastrointestinal DLBCL subclassification is closely correlated with local lymph node metastasis, and this in combination with the expression of CD10 could be used to predict the prognosis of patients with gastrointestinal DLBCL.
